Q2-osavuosiraportti
69 päivää sitten‧29 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
3 853
Myynti
Määrä
14 186
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 777 | - | - | ||
| 782 | - | - | ||
| 192 | - | - | ||
| 102 | - | - | ||
| 697 | - | - |
Ylin
1,298VWAP
Alin
1,274VaihtoMäärä
0,1 86 351
VWAP
Ylin
1,298Alin
1,274VaihtoMäärä
0,1 86 351
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 86 351 | 86 351 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 86 351 | 86 351 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
1 päivä sitten·Casper Larsen has shared this video on Facebook, where CB talks about Bioporto and the NGAL test. If you are familiar with how the test works, you can also set the marker to 12.57. https://www.youtube.com/watch?v=6cLKks7IhxE1 päivä sitten·I hope CB is more clear-headed when he announced his vision for Bioporto at the shareholders' meeting on October 7. Will he keep the guidance from 2024 or is there a new one?14 t sitten·I simply don't understand this eternal talk about visions, fancy words and expensive, clever formulations. Bioporto has, roughly speaking, a turnover like an overgrown hot dog stand. They can't figure out how to sell, even though they claim to have a unique product. In that light, instead of clever talk, in my world Bioporto needs a man of action, of execution. A man who understands how to get the dirty footwork that can often be associated with sales going. No product sells itself, which is clearly what Bioporto has always believed. The company doesn't need YET another man who thinks expensive formulations in themselves can increase sales. It needs a man who can make things happen
16.10.·Upcoming update of KDIGO Guidelines - expected end of 2025 - beginning of 2026. A small summary of which biomarkers may come into play according to ChatGPT. The hope for BioPorto and us shareholders is that NGAL will be included. ————————————————- KDIGO Biomarker Status 2025 – Expected New Candidates This overview summarizes the most promising biomarkers that are expected to be considered in upcoming KDIGO guidelines for chronic and acute kidney disease (CKD/AKI). The focus is on biomarkers with documented clinical potential for risk stratification, early damage identification or decision support. 1. Urinary Dickkopf-3 (uDKK3) • Associated with tubular stress and accelerated GFR loss. • Strong prognostic value in several cohorts (CKD, T2DM, heart failure). • Need: international standardization and cutoffs. → Expected KDIGO role: supplementary risk marker. 2. NGAL (Neutrophil Gelatinase-Associated Lipocalin) • Early tubular injury marker (urine/plasma). • Good evidence in AKI; increasing data in CKD. → Expected role: clinically relevant in AKI, research status in CKD. 3. KIM-1 (Kidney Injury Molecule-1) • Indicator of proximal tubular injury. • Associated with progression in diabetic and hypertensive nephropathy. → Expected role: research marker / validation in specific diagnoses. 4. TIMP-2 IGFBP7 (NephroCheck) • Combined biomarker of cell cycle arrest (AKI risk). • FDA-approved in certain ICU/AKI indications. → Expected role: strong in AKI guidelines, limited CKD evidence. 5. Multi-omics (proteomics / metabolomics / genetic panels) • Promising combination approaches for prediction and stratification. • Requires validation, harmonization and cost–effectiveness assessment. → Expected role: research recommendation in the next KDIGO edition. KDIGO criteria for biomarker inclusion 1. Robust prospective validation in multiple populations. 2. Clinical utility (changes decisions and improves outcomes). 3. Standardized assays and international cutoffs. 4. Documented implementability and cost-effectiveness. Sources: KDIGO 2024 CKD Guideline; KDIGO 2025 IgAN/IgAV Guideline; ISN Journal Summaries 2025; PMC & ScienceDirect reviews (2024–202517.10.·You could try asking ChatGPT what KDIGO is. Then you will get the following answer: KDIGO stands for Kidney Disease: Improving Global Outcomes. It is an international non-profit organization that works to improve the treatment of kidney disease worldwide. KDIGO prepares and updates clinical guidelines for the diagnosis, treatment and follow-up of patients with various kidney diseases. Key points about KDIGO: • 🧠 Purpose: To promote global standardization and quality in the treatment of kidney diseases. • 📚 Guidelines: KDIGO publishes evidence-based guidelines on, among other things, • AKI (Acute Kidney Injury) • CKD (Chronic Kidney Disease) • Transplantation • Blood pressure and diabetes in kidney disease • Mineral and bone disorders (CKD-MBD) • 🌍 Use: KDIGO guidelines are used by nephrologists, clinicians and hospitals worldwide as the gold standard for treatment and research. KDIGO guidelines are continuously updated as new research and biomarkers become available — for example, in AKI and CKD, which you have previously asked about.
14.10.·I have some questions for BioPorto: If/WHEN the adult area is also approved according to plan... Will it then be another 1.5 years before the test is sold via a commercial platform? And if not, what should the difference be? Finally: It's been a long time since PME and the board made a financial/sales "forecast". Why isn't this changed? When sales are as they are? -- 1) WHEN DOES BIOPORTO EXPECT TO EXPAND THE SHARE CAPITAL? 2) WHICH INVESTORS DOES BIOPORTO EXPECT TO USE IN A CAPITAL EXPANSION? Regards, Bakerbrød- 9.10.·This article is paid for by Bioporto https://borsen.dk/sponsored/bioporto-ser-markant-vaekstfremgang-de-kommende-ar
16.10.·Even though the article is written and paid for by Bioporto, Bioporto is legally responsible for not misleading the market and the actions. If the article promises growth, approvals or strategic progress, it must be factually correct and not appear to be price manipulation. - 6.10.·"Bioporto sees significant growth progress..."! Within a few months, it will be "refueled" again via the shareholders! So WHY is this story coming now?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
69 päivää sitten‧29 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 1 päivä sitten·Casper Larsen has shared this video on Facebook, where CB talks about Bioporto and the NGAL test. If you are familiar with how the test works, you can also set the marker to 12.57. https://www.youtube.com/watch?v=6cLKks7IhxE1 päivä sitten·I hope CB is more clear-headed when he announced his vision for Bioporto at the shareholders' meeting on October 7. Will he keep the guidance from 2024 or is there a new one?14 t sitten·I simply don't understand this eternal talk about visions, fancy words and expensive, clever formulations. Bioporto has, roughly speaking, a turnover like an overgrown hot dog stand. They can't figure out how to sell, even though they claim to have a unique product. In that light, instead of clever talk, in my world Bioporto needs a man of action, of execution. A man who understands how to get the dirty footwork that can often be associated with sales going. No product sells itself, which is clearly what Bioporto has always believed. The company doesn't need YET another man who thinks expensive formulations in themselves can increase sales. It needs a man who can make things happen
- 16.10.·Upcoming update of KDIGO Guidelines - expected end of 2025 - beginning of 2026. A small summary of which biomarkers may come into play according to ChatGPT. The hope for BioPorto and us shareholders is that NGAL will be included. ————————————————- KDIGO Biomarker Status 2025 – Expected New Candidates This overview summarizes the most promising biomarkers that are expected to be considered in upcoming KDIGO guidelines for chronic and acute kidney disease (CKD/AKI). The focus is on biomarkers with documented clinical potential for risk stratification, early damage identification or decision support. 1. Urinary Dickkopf-3 (uDKK3) • Associated with tubular stress and accelerated GFR loss. • Strong prognostic value in several cohorts (CKD, T2DM, heart failure). • Need: international standardization and cutoffs. → Expected KDIGO role: supplementary risk marker. 2. NGAL (Neutrophil Gelatinase-Associated Lipocalin) • Early tubular injury marker (urine/plasma). • Good evidence in AKI; increasing data in CKD. → Expected role: clinically relevant in AKI, research status in CKD. 3. KIM-1 (Kidney Injury Molecule-1) • Indicator of proximal tubular injury. • Associated with progression in diabetic and hypertensive nephropathy. → Expected role: research marker / validation in specific diagnoses. 4. TIMP-2 IGFBP7 (NephroCheck) • Combined biomarker of cell cycle arrest (AKI risk). • FDA-approved in certain ICU/AKI indications. → Expected role: strong in AKI guidelines, limited CKD evidence. 5. Multi-omics (proteomics / metabolomics / genetic panels) • Promising combination approaches for prediction and stratification. • Requires validation, harmonization and cost–effectiveness assessment. → Expected role: research recommendation in the next KDIGO edition. KDIGO criteria for biomarker inclusion 1. Robust prospective validation in multiple populations. 2. Clinical utility (changes decisions and improves outcomes). 3. Standardized assays and international cutoffs. 4. Documented implementability and cost-effectiveness. Sources: KDIGO 2024 CKD Guideline; KDIGO 2025 IgAN/IgAV Guideline; ISN Journal Summaries 2025; PMC & ScienceDirect reviews (2024–202517.10.·You could try asking ChatGPT what KDIGO is. Then you will get the following answer: KDIGO stands for Kidney Disease: Improving Global Outcomes. It is an international non-profit organization that works to improve the treatment of kidney disease worldwide. KDIGO prepares and updates clinical guidelines for the diagnosis, treatment and follow-up of patients with various kidney diseases. Key points about KDIGO: • 🧠 Purpose: To promote global standardization and quality in the treatment of kidney diseases. • 📚 Guidelines: KDIGO publishes evidence-based guidelines on, among other things, • AKI (Acute Kidney Injury) • CKD (Chronic Kidney Disease) • Transplantation • Blood pressure and diabetes in kidney disease • Mineral and bone disorders (CKD-MBD) • 🌍 Use: KDIGO guidelines are used by nephrologists, clinicians and hospitals worldwide as the gold standard for treatment and research. KDIGO guidelines are continuously updated as new research and biomarkers become available — for example, in AKI and CKD, which you have previously asked about.
- 14.10.·I have some questions for BioPorto: If/WHEN the adult area is also approved according to plan... Will it then be another 1.5 years before the test is sold via a commercial platform? And if not, what should the difference be? Finally: It's been a long time since PME and the board made a financial/sales "forecast". Why isn't this changed? When sales are as they are? -- 1) WHEN DOES BIOPORTO EXPECT TO EXPAND THE SHARE CAPITAL? 2) WHICH INVESTORS DOES BIOPORTO EXPECT TO USE IN A CAPITAL EXPANSION? Regards, Bakerbrød
- 9.10.·This article is paid for by Bioporto https://borsen.dk/sponsored/bioporto-ser-markant-vaekstfremgang-de-kommende-ar16.10.·Even though the article is written and paid for by Bioporto, Bioporto is legally responsible for not misleading the market and the actions. If the article promises growth, approvals or strategic progress, it must be factually correct and not appear to be price manipulation.
- 6.10.·"Bioporto sees significant growth progress..."! Within a few months, it will be "refueled" again via the shareholders! So WHY is this story coming now?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
3 853
Myynti
Määrä
14 186
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 777 | - | - | ||
| 782 | - | - | ||
| 192 | - | - | ||
| 102 | - | - | ||
| 697 | - | - |
Ylin
1,298VWAP
Alin
1,274VaihtoMäärä
0,1 86 351
VWAP
Ylin
1,298Alin
1,274VaihtoMäärä
0,1 86 351
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 86 351 | 86 351 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 86 351 | 86 351 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
69 päivää sitten‧29 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 1 päivä sitten·Casper Larsen has shared this video on Facebook, where CB talks about Bioporto and the NGAL test. If you are familiar with how the test works, you can also set the marker to 12.57. https://www.youtube.com/watch?v=6cLKks7IhxE1 päivä sitten·I hope CB is more clear-headed when he announced his vision for Bioporto at the shareholders' meeting on October 7. Will he keep the guidance from 2024 or is there a new one?14 t sitten·I simply don't understand this eternal talk about visions, fancy words and expensive, clever formulations. Bioporto has, roughly speaking, a turnover like an overgrown hot dog stand. They can't figure out how to sell, even though they claim to have a unique product. In that light, instead of clever talk, in my world Bioporto needs a man of action, of execution. A man who understands how to get the dirty footwork that can often be associated with sales going. No product sells itself, which is clearly what Bioporto has always believed. The company doesn't need YET another man who thinks expensive formulations in themselves can increase sales. It needs a man who can make things happen
- 16.10.·Upcoming update of KDIGO Guidelines - expected end of 2025 - beginning of 2026. A small summary of which biomarkers may come into play according to ChatGPT. The hope for BioPorto and us shareholders is that NGAL will be included. ————————————————- KDIGO Biomarker Status 2025 – Expected New Candidates This overview summarizes the most promising biomarkers that are expected to be considered in upcoming KDIGO guidelines for chronic and acute kidney disease (CKD/AKI). The focus is on biomarkers with documented clinical potential for risk stratification, early damage identification or decision support. 1. Urinary Dickkopf-3 (uDKK3) • Associated with tubular stress and accelerated GFR loss. • Strong prognostic value in several cohorts (CKD, T2DM, heart failure). • Need: international standardization and cutoffs. → Expected KDIGO role: supplementary risk marker. 2. NGAL (Neutrophil Gelatinase-Associated Lipocalin) • Early tubular injury marker (urine/plasma). • Good evidence in AKI; increasing data in CKD. → Expected role: clinically relevant in AKI, research status in CKD. 3. KIM-1 (Kidney Injury Molecule-1) • Indicator of proximal tubular injury. • Associated with progression in diabetic and hypertensive nephropathy. → Expected role: research marker / validation in specific diagnoses. 4. TIMP-2 IGFBP7 (NephroCheck) • Combined biomarker of cell cycle arrest (AKI risk). • FDA-approved in certain ICU/AKI indications. → Expected role: strong in AKI guidelines, limited CKD evidence. 5. Multi-omics (proteomics / metabolomics / genetic panels) • Promising combination approaches for prediction and stratification. • Requires validation, harmonization and cost–effectiveness assessment. → Expected role: research recommendation in the next KDIGO edition. KDIGO criteria for biomarker inclusion 1. Robust prospective validation in multiple populations. 2. Clinical utility (changes decisions and improves outcomes). 3. Standardized assays and international cutoffs. 4. Documented implementability and cost-effectiveness. Sources: KDIGO 2024 CKD Guideline; KDIGO 2025 IgAN/IgAV Guideline; ISN Journal Summaries 2025; PMC & ScienceDirect reviews (2024–202517.10.·You could try asking ChatGPT what KDIGO is. Then you will get the following answer: KDIGO stands for Kidney Disease: Improving Global Outcomes. It is an international non-profit organization that works to improve the treatment of kidney disease worldwide. KDIGO prepares and updates clinical guidelines for the diagnosis, treatment and follow-up of patients with various kidney diseases. Key points about KDIGO: • 🧠 Purpose: To promote global standardization and quality in the treatment of kidney diseases. • 📚 Guidelines: KDIGO publishes evidence-based guidelines on, among other things, • AKI (Acute Kidney Injury) • CKD (Chronic Kidney Disease) • Transplantation • Blood pressure and diabetes in kidney disease • Mineral and bone disorders (CKD-MBD) • 🌍 Use: KDIGO guidelines are used by nephrologists, clinicians and hospitals worldwide as the gold standard for treatment and research. KDIGO guidelines are continuously updated as new research and biomarkers become available — for example, in AKI and CKD, which you have previously asked about.
- 14.10.·I have some questions for BioPorto: If/WHEN the adult area is also approved according to plan... Will it then be another 1.5 years before the test is sold via a commercial platform? And if not, what should the difference be? Finally: It's been a long time since PME and the board made a financial/sales "forecast". Why isn't this changed? When sales are as they are? -- 1) WHEN DOES BIOPORTO EXPECT TO EXPAND THE SHARE CAPITAL? 2) WHICH INVESTORS DOES BIOPORTO EXPECT TO USE IN A CAPITAL EXPANSION? Regards, Bakerbrød
- 9.10.·This article is paid for by Bioporto https://borsen.dk/sponsored/bioporto-ser-markant-vaekstfremgang-de-kommende-ar16.10.·Even though the article is written and paid for by Bioporto, Bioporto is legally responsible for not misleading the market and the actions. If the article promises growth, approvals or strategic progress, it must be factually correct and not appear to be price manipulation.
- 6.10.·"Bioporto sees significant growth progress..."! Within a few months, it will be "refueled" again via the shareholders! So WHY is this story coming now?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
3 853
Myynti
Määrä
14 186
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 777 | - | - | ||
| 782 | - | - | ||
| 192 | - | - | ||
| 102 | - | - | ||
| 697 | - | - |
Ylin
1,298VWAP
Alin
1,274VaihtoMäärä
0,1 86 351
VWAP
Ylin
1,298Alin
1,274VaihtoMäärä
0,1 86 351
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 86 351 | 86 351 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 86 351 | 86 351 | 0 | 0 |